

INDIAN HYPERTENSION GUIDELINES-II

References:

1. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. *Prospective Studies Collaboration. Lancet.* 2002;360: 1903-1913.
2. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. *Hypertension* 2003; 42:1206-52.
3. Indian Guidelines Management of Hypertension 2001. *Hypertension India* 2001; 15 (2): 1-34.
4. Meissner I, Whisnant JP, Sheps S, Schwartz G, O'Fallon WM, Coralt J, et al. Stroke prevention: assessment of risk in a community: the SPARC study, part 1: blood pressure trends, treatment and control (abstract). *Ann Neurol* 1997;42:433.
5. Brown RD Jr, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers D. Stroke incidence, prevalence and survival: Secular trends in Rochester, Minnesota, through 1989. *Stroke* 1996; 27:373-380.
6. Franklin SS, Larson MG, Khan SA, Wong ND, Leip EP, Kannel WB, et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. *Circulation.* 2001;103:1245-1249.
7. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, et al. Success and predictors of blood pressure control in diverse North American settings: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *J Clin Hypertens (Greenwich).* 2002;4:393-404.
8. Black HR, Elliott WJ, Neaton JD, Grandits G, Grambsch P, Grimm R, et al. Baseline characteristics and early blood pressure control in the CONVINCE trial. *Hypertension.* 2001;37:12-18.
9. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, et. al Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. *J Hum Hyperten* 2004; 18: 139-185.
10. Vasan RS, Larson MG, Leip EP, Evans JC, O'Donnell CJ, Kannel WB, et al . Impact of high-normal BP on the risk of cardiovascular disease. *New Engl J Med* 2001; 345:1291-1297.
11. Gupta R. Trends in hypertension epidemiology in India. *J Hum Hypertens.* 2004; 18: 73-78.
12. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. *Lancet* 2005; 365 (9455): 217-223.
13. Anand MP. Epidemiology of Hypertension. In: Anand MP and Billimoria AR eds. *Hypertension an international monograph* 2001. New Delhi IJCP 2001; 10 - 25.
14. Bharucha NE, Kuruvilla T. *BMC Public Health* 2003; 3:1.
15. Deepa R, Pradeepa R, Shanthirani CS, Mohan V. Association of hypertension with cluster of insulin resistance syndrome factors: the Chennai Urban Population Study (CUPS-12) *Acta Diabetologica* 2004; 41(2): 49-55.
16. Ashavaid TF, Todur SP, Dherai AJ. Health Status of Indian Population - current Scenario *J Assoc Physicians India.* 2004; 52:363-69.
17. Shanthirani CS, Pradeepa R, Deepa R, Premlatha G, Saroja R, Mohan V. Prevalence and risk factors of hypertension in a selected South Indian population. The Chennai Urban Population Study. *J Assoc. Physicians India* 2003; 51: 20-27.
18. Hazarika NC, Narain K, Biswas D, Kalita HC, Mahanta J. Hypertension in the native rural population of Assam. *Natl Med J India* 2004; 17(6): 300-4.
19. Thankappan KR, Sivasankaran S, Khader SA , Padmanabhan PG, Sarma PS, Mini GK, et al. Prevalence, Correlates, Awareness, Treatment, and Control of Hypertension in Kumarakom, Kerala: Baseline Results of a Community-Based Intervention Program. *Indian Heart J* 2006; 58: 28-33.
20. Mohan JC. Prevalence, awareness, treatment, control, and risk factors of hypertension in India and its neighborhood: Newer data and older perspective *Indian Heart J.* 2006;58:7-9.
21. Hypertension Study Group. Prevalence, awareness, treatment and control of hypertension among the elderly in Bangladesh and India: a multicentre study. *Bulletin of the World Health Organization* 2001;79:490-500.

INDIAN HYPERTENSION GUIDELINES-II

22. Kario K, Pickering TG, Umeda Y, Hoshida S, Hoshida Y, Morinari M et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives a prospective study. *Circulation* 2003;107:1401-06.
23. 2003 European Society of Hypertension- European Society of Cardiology guidelines for the management of arterial hypertension. *J Hypertens*. 2003;21:1011-1053.
24. Sutton-Tyrrell K, Bostom A, Selhub J, Zeigler-Johnson C: High homocysteine levels are independently related to isolated systolic hypertension in older adults. *Circulation* 1997;96:1745-1749.
25. Mendis S, Athauda SB, Naser M, Takahashi K: Association between hyperhomocysteinemia and hypertension in Sri Lankans. *J Int Med Res* 1999;27:38-44.
26. Lip GY, Edmunds E, Martin SC, Jones AF, Blann AD, Beevers DG: A pilot study of homocyst(e)ine levels in essential hypertension: relationship to von Willebrand factor, an index of endothelial damage. *Am J Hypertens* 2001;14:627-631.
27. Scott J. Homocysteine and cardiovascular risk. *Am J Clin Nutr* 2000;72:333-334.
28. Clarke R. An updated review of the published studies of homocysteine and cardiovascular disease. *Int J Epidemiol* 2002;31:70-1.
29. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Menard J, et al for HOT Study group. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: Principle results of the Hypertension Optimal Treatment (HOT) randomized trial. *Lancet* 1998; 351 :1755-1762.
30. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. *BMJ* 1998; 317:703-713.
31. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. *Lancet* 2001; 358:1033-41.
32. Izzo JL, Levy D, Black HR. Importance of systolic blood pressure in older Americans. *Hypertension* 2000; 35: 1021-1024.
33. The Heart outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin converting enzyme inhibitor, ramipril on cardiovascular events in high risk patients N. *Engl J Med*. 2000 ; 342 : 145-53.
34. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA* 2002; 288:2981-2997.
35. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Diuretic Versus -Blocker as First-Step Antihypertensive Therapy Final Results From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Hypertension*. 2003; 42:239-46.
36. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. *Lancet* 1997;350:757-764.
37. Wang J, Staessen JA, Gong L, Liu L for the Systolic Hypertension in China (Syst- China) Collaborative Group. Chinese Trial on Isolated Systolic Hypertension in the Elderly. *Arch Intern Med* 2000; 160:211-220.
38. SHEP Cooperative Research Group. Prevention of Stroke by antihypertensive drug treatment in older persons with isolated Systolic hypertension. Final results of the Systolic hypertension in the Elderly Program (SHEP). *JAMA*. 1991;265(24):3255- 64.
39. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al for the ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. *Lancet* 2005; 366: 895-906.
40. Frohlich ED. Treating Hypertension - What Are We to Believe? *N Engl J Med* 2003; 348:639-641.
41. Whelton PK, Appel LJ, Espeland MA, Applegate WB, Ettinger Jr WH, Kostis JB, et al. For the TONE collaborative research group. Sodium reduction and weight reduction in treatment of hypertension in older patients. A randomised controlled Trial Of Non-pharmacological interventions in the Elderly (TONE). *JAMA* 1998;279:839-846.

INDIAN HYPERTENSION GUIDELINES-II

42. Stamier I, Cagguila AW, Grandito GA. Relation of body mass and alcohol, nutrient, fibre and caffeine intake to blood pressure in the special intervention and usual care groups in the Multiple Risk Factor Intervention Trial. *Am J Clin Nutr* 1997; 65 (suppl): 338S-365S.
43. Puddey IB, Parker M, Beiten LJ, Vandongen R, Maseree JRL. Effects of alcohol and calorie restriction on blood pressure and serum lipids in overweight men. *Hypertension* 1992; 20:533-541.
44. Greenberg G, Thompson SG, Brennan PJ. The relationship between smoking and the response to antihypertensive treatment in mild hypertensives in the Medical Research Council's trial of treatment. *Int J Epidemiol* 1987; 16:225-230 F.
45. Gupta R, Gurm H, Bartholomew JR. Smokeless Tobacco and Cardiovascular Risk *Arch Intern Med* 2004; 164:1845-1849.
46. US Department of Health and Human Services. The Health Benefits of Smoking Cessation A Report of the Surgeon General Rockville. MD: Centers for Disease Control. Center for Chronic Disease Prevention and Health Promotion. Office on Smoking and Health; DHHS publication no. (CDC) 90:8416: 1990 Pr.
47. Patel C. 12-month follow-up of yoga and bio-feedback in the management of hypertension. *Lancet* 1975; 1 (7898):62-64.
48. Sunder S, Agrawal SK, Singh VP, Bhattacharya SK, Udupa KN, Vaish SK. Role of yoga in management of essential hypertension. *Acta Cardiol* 1984; 39(3):203-208.
49. Datey KK. Role of biofeedback training in hypertension and stress. *J Postgrad Med* 1980; 26:68-73.
50. Damodaran A, Malathi A, Patil N, Shah N, Suryavanshi, Marathe S. Therapeutic potential of yoga practices in modifying cardiovascular risk profile in middle aged men and women. *J Assoc Physicians India*. 2002; 50(5):633-40.
51. Rouse IL, Armstrong BD, Beilin LJ. The relationship of blood pressure to diet and lifestyle in two religious populations, *J Hypertens*. 1983; 1:65-71.
52. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM. et al. A clinical trial of the effects of dietary patterns on blood pressure *N Engl J Med* 1997; 336:1117-1124.
53. Bao DG, Mori TA, Burke V, Puddey IB, Beilin LJ. Effects of dietary fish and weight reduction on ambulatory blood pressure in overweight hypertensives. *Hypertension* 1998; 32:710-717.
54. Whelton PK, He J, Cutler JA, Brancati FL, Appel LJ, Follmann D, et al. Effects of oral potassium on blood pressure: Meta analysis of randomized controlled trials. *JAMA* 1999; 277:1624-1632.
55. Srilakshmi B. Diet in diseases of cardiovascular system. In: Srilakshmi B editor. *Dietetics*. Revised. 5th ed. New Delhi: New Age International (P)Ltd; 2005.p. 189-213.
56. Srilakshmi B. Diet in diseases of Kidney. In: Srilakshmi B editor. *Dietetics*. Revised. 5th ed. New Delhi: New Age International (P)Ltd; 2005.p. 267-291.
57. Gavras H, Gavras I. On the JNC V report. A different point of view. *Am J Hypertens* 1994; 7:288-293.
58. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively designed overviews of randomised trials. *Lancet* 2003; 362: 1527-1535.
59. Hansson L, Hedneer T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, et al. Randomised trial of effect of calcium antagonists compared with diuretics and B-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. *Lancet* 2000; 356:359-365.
60. Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. *N Engl Med* 1996; 335:1107-1114.
61. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. *N Engl Med* 2000; 342:145-153.
62. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet* 2002; 359(9311): 995-1003.

INDIAN HYPERTENSION GUIDELINES-II

63. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al, for the VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. *Lancet* 2004; 363: 2022-2031.
64. Varma S, Strauss M. Angiotensin receptor blockers and myocardial infarction. *BMJ* 2004; 329:1248-1249.
65. Hypertension Management in Adults With Diabetes. Position Statement-American Diabetes Association. *Diabetes Care* 2004;27:S65-67.
66. ALLHAT officers and coordinators. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. The Antihypertensive and lipid lowering treatment to prevent Heart Attack Trial (ALLHAT). *JAMA* 2000; 283:1967-1975.
67. The Heart Outcomes Prevention Evaluation Study Investigators. Vitamin E supplementation and cardiovascular events in high-risk patients. *N Engl J Med* 2000; 342:154-60.
68. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo controlled trial. *Lancet*. 2002; 360:7-22.
69. Berglund G, Andersson O, Wilhelmsen L. Prevalence of primary and secondary hypertension: Studies in a random population sample. *BMJ* 1976; 2:554-556.
70. Danielson M, Dammstorm BG. The prevalence of secondary and curable hypertension. *Acta Med Scand* 1981; 209:451-455.
71. Birkenhager WH, De Leeuw PW. Hypertension, antihypertensive treatment and kidney. *Blood Pressure* 1992;1:201-207.
72. Laskow DA, Curtiss JJ. Post transplant hypertension. *Am J Hypertens* 1990; 3:721-725.
73. Chugh KS, Jain S, Sakhuja V, Malik N, Gupta A, Sehgal S, et. al Renovascular hypertension due to Takayasu's Arteritis among Indian patients. *Q J Med* 1992; 85:833-843.
74. Panja M, Kumar S, Sarkar CN, Sinha DP, Ray S, Chatterjee A, et al. Hypertension in young in eastern India. *Indian Heart J* 1996; 48:663-666.
75. Beard CM, Sheps SG, Kurland LT, Carney JA, Lie JT. Occurrence of pheochromocytoma in Rochester, Minnesota 1950 through 1979. *Mayo Clin Proc* 1983; 58:802-804.
76. Brano EL, Gittord RW Je. Pheochromocytoma: Diagnosis, localisation and management. *N Engl J Med* 1984; 311 :1298-1303.
77. Frohlich ED. Classic papers symposium, History of medicine series: Surrogate indexes of target organ involvement in hypertension. *Am J Med Sci* 1996; 312 :225-228.
78. Zanchetti A, Sleight P, Birkenhager WH. Evaluation of organ damage in hypertension. *J Hypertens* 1993;11:875-882.
79. Kannel WB. Left ventricular hypertrophy as a risk factor: The Framingham experience. *J Hypertens* 1991; 9(Supl 2):53-59.
80. Reddy KS. Cardiovascular diseases in India. *World health statistics quarterly* 1993; 46(2): 101-107.
81. Eastern Stroke and Coronary Heart Disease Collaborative Research Group. Blood pressure, cholesterol and stroke in Eastern Asia. *Lancet* 1998; 352 (9143): 1801-1807
82. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. *Lancet* 1990; 335:765-774.
83. Prospective Studies Collaboration. Cholesterol, diastolic blood pressure and stroke: 13,000 strokes in 45,000 people in 45 prospective cohorts. *Lancet* 1995; 346: 1647-1653.
84. Rosansky SJ, Hoover DR, King L, Gibson J. The association of blood pressure levels and change in renal functions in hypertension and nonhypertensive subjects. *Arch Int Med* 1990; 150:2073-2074.
85. Kannel WB, Stampfer MJ, Castelli WP, Verter J. The Prognostic significance of proteinuria: the Framingham Study. *Am Heart J* 1984; 108: 1347-1352.

INDIAN HYPERTENSION GUIDELINES-II

86. Ruilope LM. Proteinuria and renal function. *Blood Pressure* 1993; 2 (Suppl.1): 55-58.
87. Lewis EJ, Hunsicker LG, Rodby RA, Collaborative Study Group. A Clinical trial 2 diabetic nephropathy. *Am J Kidney Dis* 2001; 38 (4 Suppl. 1) : S 191-194
88. Wong TY, Mitchell P. Hypertensive Retinopathy. *N Engl J Med* 2004; 351:2310-17.
89. Oakley CM. Aortic dissection. *Q J Med* 1991;79:357-380.
90. Simpson DC. Etiology and prevalence of hypertension in diabetic patients. *Diabetes Care* 1988; 11; 821-827.
91. Joshi S, Shah SN. Rising Global burden of Diabetes. *The Asian J Diab* 1999; III: 13-15.
92. Estacio RO, Jeffers SW, Elisa WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared to enalapril on cardiovascular outcomes in patients with non-insulin dependent diabetes and hypertension. *N Engl J Med* 1998 ;338: 645-652.
93. Klag MJ, Whetton PK, Randall BL, Neaton JD, Brancati FL, Ford CE et al. Blood pressure and end stage renal diseases in men. *N Engl J Med* 1996; 334:13-18.
94. Lazarus JM, Bourgoignie JJ, Buckalew VM, Greene T, Levey AS, Milas NC, et al. for the Modification of Diet in Renal Disease Study Group. Achievement and safety of a low blood pressure goal in chronic renal disease: the Modification of Diet in Renal Disease Study Group. *Hypertension* 1997; 29:641-650.
95. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancett FL, Stamper J. End-stage renal disease in African-American and white men: 16-year MRFIT findings. *JAMA* 1997; 277:293-1298.
96. Palmer BF. Renal dysfunction complicating treatment of hypertension. *N Engl J Med* 2002; 347(16):1256-1261.
97. Parving HH, Tarnow L, Rossing P. Renal Protection in diabetes- an emerging role for calcium antagonists. *Cardiology* 1997; 88(suppl.):56-62.
98. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R et al. Preserving Renal Function in Adults with Hypertension and Diabetes: A Consensus Approach. *Am J Kidney Dis* 2000; 36(3): 646-661.
99. The INDANA (INdividual Data ANalysis of Antihypertensive interventional trials) Project Collaborators, Gueyffier F, Boissel J-P, Boutitie F, Pocock S, Coope J, Cutler J. Effect of antihypertensive treatment in patients having already suffered from stroke. Gathering the evidence. *Stroke* 1997; 28: 2557-2562.
100. Spengos K, Tsivgoulis G, Zakopoulos N. Blood pressure management in acute stroke: a long standing debate. *European Neurology* 2006; 55:123-135.
101. Lewis CE, Grandits A, Flack J, McDonald R, Elmer PJ. Efficacy and tolerance of antihypertensive treatment in men and women with stage 1 diastolic hypertension: results of the Treatment of Mild Hypertension Study. *Arch Intern Med.* 1996; 156:377-385.
102. Lim KG, Isles GG, Hodsman GP, Lever AF, Robertson JWK. Malignant hypertension in women of childbearing age and its relation to contraceptive pill. *BMJ* 1987; 294: 1057 -1059.
103. Dudley L. Maternal mortality associated with hypertensive disorders of pregnancy in Africa, Asia, Latin America and the Caribbean. *Br J Obstet Gynaecol* 1992; 99: 547-553.
104. Lenox JW, Urugu V, Cibils LA. Effects of hypertension on pregnancy monitoring and results. *Am J Obstet Gynaecol* 1990; 163:1173-1179.
105. Maryland B. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. *Am J Obstet Gynecol* 2000; 183:S1-S22.
106. Sibal BM. Treatment of hypertension in pregnant women. *N Engl J Med* 1996; 335:257-265.
107. Lubbe WF, Hodge JV, Kellaway GSM. Antihypertensive treatment and fetal welfare in essential hypertension in pregnancy: a retrospective survey of experience with various regimens at National women's hospital Auckland 1970-80. *Jan* 1982; Vol. 95, (699):1-5.
108. Collins R, Yusuf S, Peto R. Overview of randomized trials of low dose diuretics in pregnancy. *Br Med J (Clin Res Ed)* 1985; 290:17-23.

INDIAN HYPERTENSION GUIDELINES-II

109. Roberts JM. Magnesium for pre-eclampsia and eclampsia. *N Engl J Med* 1995; 333: 250-251.
110. The Eclampsia Trial Collaborative Group: Which anti-convulsants for women with preeclampsia Evidence from collaboration Eclampsia Trial. *Lancet* 1995; 345:1455- 1466.
111. Statistical outline of India 2004-2005. Tata services Limited. Department of economics and statistics
112. Dalal PM. Hypertension: A report on community survey on casual hypertension in old Bombay, Sir. H N Hospital Research Society 1980.
113. National High Blood Pressure Education Program Working Group. National High Blood Pressure Education Program working group report on Hypertension in the elderly. *Hypertension* 1994; 23:275-85.
114. MacMahon S, Rodgers A. The effects of blood pressure reduction in older patients: an overview of five randomized controlled trials in elderly hypertensives. *Clin Exp Hypertens* 1993; 15:967-978.
115. Espeland MA, Walton PK, Kostis JB, Bahnson JL, Ettinger WH, Cutler JA. Predictors and mediators of successful long-term withdrawal from antihypertensive medications. *Arch Fam Med* 1999; 8(3):228-236.
116. Hansson L, Lindholm LH, Ekblom T, Dahlöf B, Lanke J, Scherstén B, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the swedish trial in old patients with hypertension. *Lancet* 1999; 354:1751-1756.
117. Garg R, Yusuf S. for the collaborative Group on ACE Inhibitor Trials. Overview of Randomized trials of angiotensin converting enzyme inhibitors on mortality and morbidity in patients with heart failure. *JAMA* 1995; 273:1450-1456.
118. MERIT-HF Study Group: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). *Lancet* 1999; 353:2001-2007.
119. CIBIS-II Investigators and Committees: The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. *Lancet* 1999; 353:9-13.
120. Krum H, Roecker EB, Mohacsi P, Rouleau JL, Tendera M, Coats AJS, et al. Effects of initiating carvedilol in patients with severe chronic heart failure. Results from the COPERNICUS study. *JAMA* 2003; 289:712-718.
121. Packer M, Coats AJS, Fowler MB, Hugo A, Katus HA, Krum H, Mohacsi P, et al. Effect of carvedilol on survival in severe chronic heart failure. *N Engl J Med* 2001; 344:1651-1658.
122. Australia / New Zealand Heart Failure Research Collaborative Group. Randomized, Placebo control trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease *Lancet* 1997; 349:375-380.
123. Milton Parker. European Society of Cardiology, 22nd Annual Congress, March 2000-Carvedilol Prospective randomised cumulative survival.
124. Ake Hjalmarson. Metoprolol CR/XL Randomized Interventions Trial in Heart Failure (MERIT-HF). Proceedings of the 48th Annual Conference. American College of Cardiology 7th-9th March, 1999.
125. CIBIS II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II. (CIBIS II): a randomized trial. *Lancet* 1999; 353:9-13.
126. Bamidele E O. *Curr Ther Res* 1986; 39(4); 554-557
127. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. *Prog Cardiovasc Dis* 1985; 27:335-371.
128. Deanfield JE, Detry J-MRG, Lichtlen PR, Magnani B, Sellier P, Thaulow E, for the CAPE Study Group. Amlodipine reduces transient myocardial ischemia in patients with coronary artery disease: double-blind Circadian Anti-ischemia Program in Europe (CAPE Trial). *J Am Coll Cardiol*. 1994;24:1460-1467
129. Pitt B, Byington RP, Furberg CD, Hunninghake DB, John Mancini GB, Miller ME, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. *Circulation* 2000; 102:1503-1510.

INDIAN HYPERTENSION GUIDELINES-II

130. Ryan TJ, Anderson JL, Antman EM, Braniff BA, Brooks NH, Califf RM, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction; a report of the American College of Cardiology/American Heart association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). *J Am Coll Cardiol* 1996; 28:1328-1428.
131. Pfeffer MA, Braunwald E, Moya LA, Basta L, Brown EJ, Cuddy TE, et al. for the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction; results of the Survival and Ventricular Enlargement Trials. *N Engl J Med* 1992; 327:669-677.
132. Lonn EM, Yusuf S, Jha P, Montague TJ, Teo KK, Benedict CR, et. al Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. *Circulation* 1994; 90:2056-2069.
133. Joglekar SJ, Nanivadekar AS. Dyslipidemia- A prevalence of lipid and glycemic abnormalities in hypertensive patients: A retrospective study. *Indian Heart J* 1996; 371-374.
134. Sever PS, Dahlof B, Poulter NR, Wedet H, Beevers G, Caulfield M et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. *Lancet* 2003; 361:1149-1158.
135. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. *JAMA* 2001; 285 (19): 2486-97.
136. Background. The IDF consensus worldwide definition of the metabolic syndrome. Available on http://www.idf.org/webdata/docs/IDF_Metasyndrome_definition_pdf. Last accessed on 25.10.2005.
137. Enas EA, Senthilkumar A, Juturu V, Gupta R. Coronary Artery Disease in Women. *Indian Heart J* 2001; 53(3): 282-292.
138. Misra A, Wasir JS, Pandey RM. An Evaluation of Candidate Definitions of the Metabolic. Syndrome in Adult Asian Indians. *Diabetes Care* 2005; 28:398-403.
139. World Health Organization (WHO) 2000 Steering Committee of the Western Pacific Region of the WHO, the International Association for the Study of Obesity Task Force. *The Asia-Pacific Perspective: Redefining Obesity and its Treatment*. Geneva: WHO, 2000.
140. Sharma AM, Pischon T, Engeli S, Scholze J. Choice of drug treatment for obesity-related hypertension: where is the evidence? *J Hypertension* 2001; 19: 667-674.
141. Keulen L, Henricksen EJ, Jacob S, Lang R. Antihypertensive Treatment and Cardiovascular Risk Management in Patients with the Metabolic Syndrome - Focus on SNS and Insulin Resistance. *J Clin Basic Cardiol* 2001; 4: 193-195.
142. Douketis JD, Sharma AM. The Management of Hypertension in the Overweight and Obese Patient. Is Weight Reduction Sufficient? *Drugs* 2004; 64 (8): 795-803.
143. Wofford MR, Hall JE. Pathophysiology and Treatment of Obesity Hypertension. *Current Pharmaceutical Design* 2004; 10: 3621-3637.
144. Lauin P. Management of hypertension in patients with acute stroke. *Arch Intern Med* 1986; 146:66-68.
145. Herling IM. Intravenous nitroglycerine: Clinical Pharmacology and Therapeutic Consideration *Am Heart J* 1980; 108:141-149.
146. O' Mailia J, Sander G, Giles T. Nifedipine associated myocardial ischemic or infarction in the treatment of hypertensive emergencies. *Ann Int Med* 1987; 107: 185-186.